Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Malvern Publishes New Whitepaper that Explores AQbD

Published: Friday, May 16, 2014
Last Updated: Friday, May 16, 2014
Bookmark and Share
The whitepaper is freely available for download from

A new whitepaper on the application of Analytical Quality by Design (AQbD) to particle size assessment has been published by Malvern Instruments. AQbD is an innovative approach to the development and validation of analytical methods that brings the benefits of Quality by Design (QbD) to pharmaceutical analysis.

Malvern’s new whitepaper, ‘Beyond SOPs - Exploring the rigor and requirements of Analytical QbD’, introduces the AQbD concept, explains the associated workflow and illustrates how to apply AQbD when developing methods for laser diffraction particle sizing. The whitepaper is freely available for download from the Malvern resource center

QbD strategies are now firmly entrenched throughout pharmaceutical development and manufacture, and the benefits of their broader application are being recognized. AQbD is the application of QbD to analytical method development, which involves systematically identifying the risks associated with the variables that may impact analysis.

It calls for a more detailed understanding of the analytical method and the factors that can influence it, to establish a design space which offers the reward of robust analytical methods that improve throughout the lifecycle of pharmaceutical product.

The whitepaper introduces the regulatory benefits of applying AQbD approach to method development and highlights the parallels between AQbD and the more established QbD workflow. It goes on to present experimental results showing how to scope the method operable design region (MODR).

This is the range of operating parameters that ensures accurate analysis, for both wet and dry laser diffraction particle size analysis. It also covers method validation and the need to implement a carefully constructed control strategy to ensure consistently robust and precise analysis.

Malvern Instruments played a leading role in the introduction of SOP-driven particle size analysis more than a decade ago and delivers the know-how, technology and instrumentation to support continuing innovation in pharmaceutical analysis.

‘Beyond SOPs - Exploring the rigor and requirements of Analytical QbD’ concludes with a review of the tools and software features of the Mastersizer 3000 that can help with the implementation of AQbD to particle size measurement.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos